Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Pfizer Inc PFE

Alternate Symbol(s):  N.PFE

Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the... see more

NYSE:PFE - Post Discussion

Pfizer Inc > Pfizer Going It Alone
View:
Post by JohnT121 on Mar 29, 2021 2:45pm

Pfizer Going It Alone

Pfizer will now go it alone in vaccine expansion without BioNTech. They see the potential in developing MRNA vaccines for all types of future treatments.  Annual COVID MRNA vaccines would be used globally and worth billions per year. This alone would translate into substaintial new recurring revenues per year for PFE . 

Also working on an oral vaccine which would be a game changer, pre-clinical studies show positive results for SARS-CoV-2 and future viruses as well.
Comment by zeropointenergy on May 07, 2021 8:51am
Question is it FDA approved ????
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities